Marisa Wexler, MS,  senior science writer—

Most hereditary angioedema (HAE) patients are able to take on-demand oral tablets of sebetralstat within 10 minutes of a swelling attack starting, and begin experiencing symptom relief within two hours, with complete resolution within about a day. That’s according to interim findings from an open-label extension Phase 3…

Genetic variants in the CC2D2B gene may affect disease severity in hereditary angioedema (HAE) types 1 and 2, according to a new study. “We demonstrated, on a large cohort of [people with HAE types 1 and 2], the importance of the CC2D2B gene as a disease-modifying factor,” the researchers…

The unusual case of a woman with drug-induced angioedema that led to a rare complication called acute compartment syndrome (ACS) in all four of her limbs was described in a recent report from Japan. ACS is a disorder in which the pressure within one of the body’s compartments —…

The once-daily oral therapy Orladeyo (berotralstat) has been approved in Brazil to prevent swelling attacks in people, 12 and older, with hereditary angioedema (HAE). The approval by the Brazilian Health Regulatory Agency (ANVISA) makes Orladeyo the first oral prophylactic (preventive) therapy authorized for HAE patients in the country.

Treatment with the experimental under-the-skin injection therapy STAR-0215 reduced the rates of monthly swelling attacks by more than 90% in people with hereditary angioedema (HAE) in a small early clinical trial. That’s according to new data announced by developer Astria Therapeutics, which further showed that HAE attacks…

Pharvaris has started a Phase 3 clinical trial called RAPIDe-3 to test an immediate-release capsule formulation of deucrictibant as an on-demand treatment to manage swelling attacks in hereditary angioedema (HAE). “We hear from the HAE community that rapid onset and complete resolution of angioedema attacks with a single,…

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded promising innovative medicine designation to sebetralstat, an experimental oral therapy KalVista Pharmaceuticals is developing as an on-demand treatment to resolve swelling attacks in hereditary angioedema (HAE). The designation is the first step in the Early Access…

Orladeyo (berotralstat), an oral therapy for preventing swelling attacks in adults and adolescents with hereditary angioedema (HAE), is now available in Italy. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), has finalized reimbursement and is recommending Orladeyo as a routine prophylactic (preventive) treatment for people with HAE,…

Note: This story was updated March 12, 2024, to clarify the data pertaining to the proportion of sebetralstat-treated swelling attacks seen in HAE patients taking part in the KONFIDENT trial. A single dose of oral sebetralstat — not the two allowed in trial — was sufficient to ease or…

Birth control pills and other changes in hormone levels are a common trigger for swelling attacks among women with rare forms of hereditary angioedema (HAE), according to a new study of patients in Portugal. “The main identified triggers were oral estrogen-containing contraceptives (in 24 of 24 women; 100%),” the…